Premium
Circulating dendritic cells deficiencies as a new biomarker in classical Hodgkin lymphoma
Author(s) -
Galati Domenico,
Zanotta Serena,
Corazzelli Gaetano,
Bruzzese Dario,
Capobianco Gaetana,
Morelli Emanuela,
Arcamone Manuela,
De Filippi Rosaria,
Pinto Antonio
Publication year - 2019
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.15676
Subject(s) - abvd , vinblastine , medicine , dacarbazine , bleomycin , biomarker , lymphoma , flow cytometry , gastroenterology , interquartile range , myeloid , oncology , immunology , chemotherapy , biology , cyclophosphamide , vincristine , biochemistry
Summary No robust biomarkers have been yet validated to identify the recurrence of disease in classical Hodgkin Lymphoma ( cHL ) patients upon induction treatment. The relevance of the inflammatory microenvironment in cHL prompted us to investigate the key immunomodulator myeloid dendritic cells type‐1 ( mDC 1), type‐2 ( mDC 2) and plasmacytoid dendritic cells ( pDC ). Blood DC levels were assessed in 52 newly diagnosed patients through multiparametric flow‐cytometry. All but two patients received ABVD regimen (doxorubicin, bleomycin, vinblastine, dacarbazine). The median counts of all DC subsets were lower in cHL patients than in healthy controls ( P < 0·001). Median mDC counts were inferior for the advanced vs early stage patients for both mDC 1s and mDC 2s ( P = 0·008; P = 0·0007 respectively). Also, median mDC 2 counts were reduced in case of bulky ( P = 0·0004) and extra‐nodal ( P = 0·046) disease. Patients with B symptoms had lower levels for mDC 1s ( P = 0·046), mDC 2s ( P = 0·009) and pDC s ( P = 0·040). All the DC subtypes increased at the end of treatment in 26 patients ( P < 0·001): 4·6‐fold for mDC 1, 2·4‐fold for mDC 2, 4·5‐fold for pDC and aligned DC s subsets with the reference frequencies and the interquartile ranges of the controls. In conclusion, DC s may contribute to the disturbed immunological interplay typical of cHL , prompting a further evaluation of their value as a potential new biomarker.